Skip to content
Back to blog

Servier To Showcase Clinical Advances Across its Oncology Pipeline at ESMO 2023

Servier data at ESMO to include updates in research and development across solid tumors, including IDH-mutant diffuse glioma, colorectal cancer and pancreatic cancer, colorectal cancer and pancreatic cancer

Paris, France – 19 October, 2023 – Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, will present data across its novel oncology pipeline at the European Society of Medical Oncology (ESMO) annual meeting in Madrid, Spain, October 20-24, 2023. These latest data highlight the breadth of Servier’s oncology pipeline and portfolio, as well as its commitment to scientific research and development for patients with high unmet needs in rare disease cancers.

“Servier is honored to bring a portfolio of data from across rare disease solid tumors to this year’s ESMO congress,” said Walid S. Kamoun, Global Head of R&D Oncology of the Servier Group. “We continue to invest significantly in oncology across the globe, and the data being presented at ESMO reflects both our commitment to the scientific research and development in rare oncology diseases, as well as our commitment to patients with high unmet needs who are often overlooked in cancer research.”

Data being presented at the congress include:

  • Proffered paper from INDIGO: a randomized, double-blinded, Phase 3 study of vorasidenib versus placebo in IDH1 or IDH2 mutant diffuse glioma,
  • Post-hoc analyses from the Phase 3 SUNLIGHT trial in metastatic colorectal cancer,
  • Overall and progression-free survival of patients with metastatic colorectal cancer from Servier’s international, non-interventional, retrospective/prospective, longitudinal PROMETCO cohort study,
  • Data in treatment-naïve metastatic adenocarcinoma of the pancreas from the NAPOLI-3 trial, sponsored by Ipsen.

“As Servier’s global footprint continues to expand, our leadership in oncology will be on full display at ESMO 2023, as evidenced by our continued investments in R&D, access and patient care,” said François Druguet, Head of Global Product Strategy Oncology of the Servier Group. “2023 has been an unprecedented year across our diversified portfolio, and we look forward to engaging with the HCP and patient communities at ESMO while reinforcing our commitment toward therapeutic progress in oncology.”

Servier data being presented at ESMO are listed below (Central European Time) and are available online on the ESMO website here.

Proffered Paper: INDIGO: A randomized, double-blinded Phase 3 study of vorasidenib versus placebo in IDH1 or IDH2 low-grade glioma

  • Date & Time: Friday, 20 October, 4:00 – 4:10 p.m.
  • Lead Author: Deborah T. Blumenthal

Poster #604P: Overall and progression-free survival of patients with metastatic colorectal cancer: a real-world perspective, longitudinal cohort study on the continuum of care (PROMETCO)

  • Date: Sunday, 22 October
  • Lead Author: Miriam Koopman

Poster #614P: Effect of KRASG12 mutations on overall survival in patients with refractory metastatic colorectal cancer: a post-hoc analysis of the phase 3 SUNLIGHT trial

  • Date: Sunday, 22 October
  • Lead Author: Josep Tabernero

Poster #613P: Effect of prior use of anti-VEGF agents on overall survival in patients with refractory metastatic colorectal cancer: a post-hoc analysis of the Phase 3 SUNLIGHT trial

  • Date: Sunday, 22 October
  • Lead Author: Gerald W. Prager

Poster #1619P: Health-related quality of life with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) EORTC QLQ-C30 results from the NAPOLI 3 trial (Ipsen)

  • Date: Monday, 23 October
  • Lead Author: Davide Melisi

Poster #1674P: VILP Registry of patients with metastatic pancreatic cancer treated with pegylated liposomal irinotecan plus 5-fluoroucil and leucovorin in the Czech Republic

  • Date: Monday, 23 October
  • Lead Author: Stanislav Batko

About Servier

Founded to serve health, Servier is a global pharmaceutical group governed by a Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world. With its unique governance model, it can fully serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. The 21,400 employees of the Group are committed to this shared vocation, a source of inspiration every day.

As a world leader in cardiology, Servier’s ambition is to become a focused and innovative player in oncology by targeting difficult and hard-to-treat cancers. That is why the Group allocates over 50% of its R&D budget to Oncology.

Neuroscience and immuno-inflammatory diseases are the future growth drivers. In these areas, Servier is focused on a limited number of diseases in which accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote access to quality care for all at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, relying on strong brands in France, Eastern Europe, Brazil and Nigeria. In all these areas, the Group includes the patient voice at each stage of the life cycle of a medicine.

Headquartered in France, Servier relies on a strong geographical footprint in over 150 countries and achieved a revenue of €4.9 billion in 2022.

For more information:   Follow us on social media: LinkedIn, Facebook, Twitter, Instagram  

About Servier in Oncology

Servier is a global leader in oncology focused on delivering meaningful therapeutic progress for the patients it serves. Governed by a non-profit foundation, Servier approaches innovation with a long-term vision, free of influence from investors and outside pressure to chase short-term monetary targets.

As a leader in oncology, Servier has significantly accelerated its investment in difficult and hard-to-tread cancers, with more than 50% of its research and development dedicated to delivering significant advances in areas of high unmet need throughout oncology with the potential to change the lives of the patients it serves. Within these areas, Servier is the leader in mutant IDH inhibition, with the first ever mutant IDH inhibitor approved in the U.S. and the European Union, and the company continues to drive the science behind targeted mutant IDH inhibition throughout its pipeline.

Servier’s commitment to therapeutic progress guides its collaboration strategy. While many companies across the industry are scaling back investments, Servier is actively building alliances, completing acquisitions, conducting licensing deals and entering new partnerships that can help to accelerate access to therapies for patients in need. With the company’s commercial expertise, global reach, scientific expertise and commitment to clinical excellence, Servier is dedicated to bringing the promise of tomorrow to the patients it serves.

More information:   

Press contact


This document contains general information about the Servier Group and its legal entities (hereinafter “Servier and its Affiliates”) and is intended for informational purposes only. The information is thought to be reliable; however, Servier and its Affiliates make no representation as to the accuracy or completeness of the information contained

herein or otherwise provided and accept no responsibility or liability, in contract, in tort, in negligence, or otherwise, should the information be found to be inaccurate or incomplete in any respect.​

Servier and its Affiliates are not acting as an advisor to the recipient of this information, and the ultimate decision to proceed with any transaction rests solely with the recipient of this information. Therefore, prior to entering into any proposed transaction, the recipient of this information should determine, without reliance upon Servier or its Affiliates, the economic risks and merits, as well as the legal, tax, and accounting characterizations and consequences, of the transaction and that it is able to assume these risks. ​

Any reliance placed on this document is done entirely at the risk of the person placing such reliance. The information contained in this document is neither an offer to sell nor the solicitation of an offer to enter into a transaction.​

The content of this document is a summary only, is not deemed to be comprehensive, and does not include all material information about Servier and its Affiliates.​

To the maximum extent permitted by applicable laws and regulations, Servier and its Affiliates disclaim all representations, warranties, conditions and guarantees, whether express, implied, statutory or of other kind, nor do they accept any duty to any person, in connection with this document. Without prejudice to the generality of the foregoing, Servier and its Affiliates do not warrant or represent that the information or opinions contained in this document are accurate or comprehensive. ​

To the maximum extent permitted by applicable laws and regulations, Servier and its Affiliates shall not be liable for any loss, damage or expense whatsoever, whether direct or indirect, howsoever arising, whether in contract, tort (including negligence), strict liability or otherwise, for direct, indirect, incidental, consequential, punitive or special damages arising out of or in connection with this document, including (without limitation) any course of action taken on the basis of the same.​

The estimates, strategies, and views expressed in this document are based upon past or current data and information and are subject to change without notice.